Re: Design and endpoints of clinical trials in patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

Affiliations

¹ European Organisation of Research and Treatment of Cancer (EORTC) Headquarters, Statistics Department, Avenue Emmanuel Mounier 83/11, 1200 Brussels, Belgium.

Comment

Laurence Collette. Eur Urol. 2008 Aug.

. 2008 Aug;54(2):462.

doi: 10.1016/j.eururo.2008.04.086.

¹ European Organisation of Research and Treatment of Cancer (EORTC) Headquarters, Statistics Department, Avenue Emmanuel Mounier 83/11, 1200 Brussels, Belgium.

No abstract available

Comment on

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Scher HI, et al. J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487. J Clin Oncol. 2008. PMID: 18309951 Free PMC article.